Abstract
Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 434-437 |
| Number of pages | 4 |
| Journal | American Journal of Hematology |
| Volume | 90 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. / Barbui, Tiziano; Vannucchi, Alessandro M.; Carobbio, Alessandra; Thiele, Jurgen; Rumi, Elisa; Gisslinger, Heinz; Rodeghiero, Francesco; Randi, Maria Luigia; Rambaldi, Alessandro; Pieri, Lisa; Pardanani, Animesh D; Passamonti, Francesco; Finazzi, Guido; Tefferi, Ayalew.
In: American Journal of Hematology, Vol. 90, No. 5, 01.05.2015, p. 434-437.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
AU - Barbui, Tiziano
AU - Vannucchi, Alessandro M.
AU - Carobbio, Alessandra
AU - Thiele, Jurgen
AU - Rumi, Elisa
AU - Gisslinger, Heinz
AU - Rodeghiero, Francesco
AU - Randi, Maria Luigia
AU - Rambaldi, Alessandro
AU - Pieri, Lisa
AU - Pardanani, Animesh D
AU - Passamonti, Francesco
AU - Finazzi, Guido
AU - Tefferi, Ayalew
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.
AB - Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.
UR - http://www.scopus.com/inward/record.url?scp=84928228394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928228394&partnerID=8YFLogxK
U2 - 10.1002/ajh.23970
DO - 10.1002/ajh.23970
M3 - Article
VL - 90
SP - 434
EP - 437
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 5
ER -